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Abstract 
Background: Acute kidney injury (AKI) is a common complication of malaria. In low resource settings, a lack of 
diagnostic tools and delayed treatment of malaria associated AKI lead to significant morbidity and mortality. The aim 
of this study was to assess the diagnostic performance of salivary urea nitrogen (SUN) dipstick to detect and monitor 
kidney disease [KD = AKI or acute kidney disease (AKD) without AKI] in malaria patients in Angola.
Methods: Patients 11–50 years old admitted with malaria at the Josina Machel (Maria‑Pia) Hospital, Luanda, Angola, 
between 2nd March and 10th May 2016 were enrolled in this study. All participants had serum creatinine (sCr), blood 
urea nitrogen (BUN) and SUN dipstick tested at the time of recruitment and daily for up to 4 days. AKD without AKI 
refers to acute renal impairment which do not fulfilled the main criteria for AKI (increases in the baseline serum creati‑
nine and/or decreases in urine output) according defined by the kidney disease improving global outcomes (KDIGO) 
guideline.
Results: Eight‑six patients were admitted with malaria diagnosis (mean age 21.5 ± 9.4 years, 71% male) and 27 (32%) 
were diagnosed with KD. The mean (± SD) sCr and BUN of the KD group at admission (day 0) were 5.38 (± 5.42) and 
99.4 (± 61.9) mg/dL, respectively. Three (3.5%) patients underwent haemodialysis and eight (9.3%) died within the 
first 4 days of hospital admission [5 (62.5%) with KD; 3 (37.5%) without kidney disease; p = 0.047]. The SUN threshold 
for KD diagnosis was tested pad #5 (SUN > 54 mg/dL). At this threshold, the SUN dipstick had a sensitivity of 67% and 
specificity of 98% to diagnose KD. The area under the receiver operating characteristics curve (ROC) for KD diagnosis 
on admission was 0.88 (95% CI 0.79–0.96). The SUN dipstick was most accurate at higher levels of BUN.
Conclusion: The SUN dipstick had reasonable sensitivity and excellent specificity when used to diagnose KD in a 
cohort of patients with malaria in a resource‑limited setting. Given the severity of presenting illness and kidney injury, 
the SUN dipstick diagnostic threshold was high (test pad #5). SUN may be used to detect AKI in patients with malaria 
in low resources settings, thus facilitating earlier access to adequate treatment, which may improve survival.
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Background
Despite control efforts, malaria remains one of the most 
common infectious diseases in more than 90 countries 
and territories worldwide (300–500  million cases per 
year estimated by the World Health Organization [1]). 
Most deaths due to the disease occur in children below 
the age of 5 years old in Africa, particularly in rural areas 
with limited or no access to medical care [2–4]. Govern-
ments of endemic countries contributed 31% of total 
funding (US$ 800  million) and the majority (74%) of 
investments were spent in the African Region followed 
by the regions of South-East Asia (7%) [4]. However, all 
these investments are not enough in some regions where 
the lack of diagnostic tools is an important problem to 
detect and treat the disease and its complications.
One of the most serious complications of malaria is the 
acute impairment of renal function, mainly in patients 
with falciparum and vivax malaria [5, 6]. The pathogen-
esis of malaria associated AKI is unclear, however, several 
factors have been suggested: tubular obstruction by para-
sitized erythrocytes; an excessive host immune response 
with reactive oxygen and nitrogen species production; 
interstitial inflammation and deposition of immune com-
plexes; hypovolaemia and renal microcirculation disor-
ders leading to acute tubular injury; and peri-infectious 
proliferative glomerular changes with thickening of the 
basement membrane [7, 8].
The presence of AKI is a strong predictor of mortal-
ity in malaria [9, 10]. In low resource settings, as in most 
African countries with high malaria incidence, AKI 
increases morbidity and mortality particularly due to 
lack of early diagnosis and treatment. Laboratory staff 
and resources are scarce and expensive in these areas 
where malaria is first diagnosed and managed [11–13]. 
The measurement of newer biomarkers such as cysta-
tin C, kidney injury molecule-1 (KIM-1) and neutrophil 
gelatinase-associated lipocalin (NGAL) to diagnose AKI 
is unavailable in developing countries, and even tests that 
are routine in higher income countries, such as serum 
creatinine (sCr), are often unavailable [14, 15]. Simple 
bedside tools to detect renal impairment can, therefore, 
facilitate early diagnosis and adequate treatment, and 
thus may improve patient outcomes [16].
While several point-of-care (POC) testing methods 
and devices such as those developed to measure serum 
creatinine at the bedsite (e.g. iSTAT ®, Stat  senso®, Pic-
colo  xpress® and others), are available to assess kidney 
function, notably at considerably lower costs compared 
to lab facilities, these tests are still too expensive for 
widespread use [16]. In addition, most tests are based 
on enzymatic methods to measure creatinine and may 
thus require refrigeration of test strips pads, rendering 
their use challenging in low resource settings with hot 
and humid climates [16]. Previous publications have 
reported the diagnostic performance of a salivary urea 
nitrogen (SUN) dipstick to detect acute and chronic 
kidney disease in both developed and developing coun-
tries in patients with different chronic kidney disease 
(CKD) stages, including patients undergoing dialysis, 
and also AKI patients with various aetiologies [17–21].
Considering malaria is a community-acquired dis-
ease, highly prevalent in many low-resource regions 
worldwide, the use of POC testing at the primary 
care facilities, in small villages, would increase the 
chances of acute kidney disease detection and referral 
to specialized care improving the chances to receive 
an adequated treatment to that serious complication, 
consequently increasing survival among this group of 
patients. The aim of this study was to evaluate the diag-
nostic performance of the salivary urea nitrogen (SUN) 
dipstick to detect and follow acute kidney disease in 
malaria patients in Angola.
Methods
Study design
A longitudinal prospective observational study was 
conducted after been approved by the Research Eth-
ics Committee from the Instituto Superior de Ciências 
de Saúde from Universidade Agostinho Neto, Luanda, 
Angola (no. 664/GD/ISCISA/UAN/2015), with the 
Hospital Josina Machel (Maria Pia) manager authoriza-
tion (no. 23/DPC/HJM/2016). The Josina Machel Hos-
pital is a tertiary hospital located in Luanda, Angola, 
reference for the treatment of chronic diseases and also 
for complicated malaria in the Luanda’s region. Patients 
between 11 and 50 years old (small kids up to 12, teen-
agers up to 18 and adults ≥ 18  years old), hospitalized 
with malaria at the Josina Machel (Maria Pia) Hospital 
in Luanda, Angola, between 2nd March and 10th May 
2016 were approached for consent. In all patients who 
agreed to participate and signed an informed consent 
form, blood was drawn at admission to measure sCr 
and BUN. In addition, the patients provided saliva sam-
ples for SUN measurements using a dipstick. Presence 
of AKI was defined according to the KDIGO criteria, 
based on sCr levels. Patients enrolled were followed for 
up to 4 days while hospitalized. Blood and salivary sam-
ples were collected daily for the measurement of sCr, 
BUN and SUN. Patients unable to give the inform con-
sent, to provide saliva samples and those with known 
CKD or with other chronic diseases which could poten-
tially cause CKD prior to the hospitalization, such as 
hypertension and diabetes, were excluded from the 
study to minimize the odds of recruiting subjects with 
preexisting kidney impairment.
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SUN measurement
Unstimulated saliva and blood were collected concur-
rently when blood was drawn. Subjects were asked to 
refrain from drinking and eating for at least 15 min prior 
to saliva collection. Saliva was sampled in a plastic cup 
and approximately 50 μL of its liquid fraction were used 
to moisten the colorimetric SUN dipstick. After 1  min 
the colour of the test pad was compared to six stand-
ardized colour fields indicating SUN concentrations of 
5–14 (colour pad #1), 15–24 (#2), 25–34 (#3), 35–54 (#4), 
55–74 (#5), and ≥ 75 (#6) mg/dL, respectively (Fig. 1 and 
Additional file 1: Figure S1).
Blood sample analysis
For BUN and sCr tests, 3–5 mL of blood were collected 
from a peripheral vein and processed in automated 
devices (Vital Scientific Flexor E180 and Flexor E450) in 
the central laboratory of the Josina Machel Hospital.
Malaria diagnosis
Diagnosis of malaria was made by either thick blood 
smear analysis or rapid malaria antigen test (SD-Bioline 
Malaria AG Pf/PAN). The tests were performed by Josina 
Machel hospital professionals, who subsequently also 
confirmed the diagnosis by direct parasite visualization 
using Giemsa-staining of a thick blood drop. All these 
tests were done on the day of patient’s inclusion into the 
study [22, 23].
Acute renal disease classification
AKI and AKD without AKI were classified according to 
KDIGO criteria, by the serum creatinine criteria only, 
because urine output of these patients was not evaluated 
during hospitalization period, thus not assessed in the 
research population as well [24]. AKD without AKI refers 
to those patients who have serum creatinine elevated at 
the admission and does not fulfill the criteria to be classi-
fied into one of the AKI stages by KDIGO neither trough 
serum creatinine nor trough urine output variation, it 
was considered acute renal impairment known or pre-
sumed to be of < 3 months duration but not fulfilling the 
main criteria for AKI according KDIGO guideline defini-
tion. In children, an assumed baseline eGFR (according 
to bedside Schwartz equation) of 100  mL/min/1.73  m2 
was used [25]. AKI and AKD without AKI were com-
bined under the kidney disease (KD) group for the statis-
tical analyses and results report.
Fig. 1 Flowchart—study population description
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Statistical analysis
Continuous data are summarized as mean ± standard 
deviation if normally distributed, otherwise as median 
and interquartile range. Differences between BUN and 
SUN (transformed to a continuous variable by choosing 
the midpoint of each test pad) are depicted with their 
95% confidence intervals. A modified Bland–Altman plot 
with BUN as the reference was also constructed.
Agreement between SUN and BUN over the entire 
period assessed using linear mixed effects models with 
the study subject as the random intercept and the meas-
urement day as the random slope. Diagnostic perfor-
mance of SUN and BUN to detect KD were analysed by 
computing the sensitivity and specificity with KD as a 
binary outcome, and the area under the receiver oper-
ating characteristics curve at each of the 4 observation 
days following the approach described previously [18]. 
Youden index was computed as follows: true positive 
(TP) was a patient with KD (as a dichotomous outcome) 
and a positive test result. A patient was considered as 
true negative (TN) if the SUN level was below the deter-
mined threshold in the absence of KD. False positive (FP) 
and false negative (FN) results were defined accordingly. 
Sensitivity was computed as TP/(TP + FN), and specific-
ity as TN/(TN + FP). Optimal diagnostic thresholds were 
determined based on the maximum of the Youden’s index 
(Youden’s index = sensitivity + specificity − 1).
A two-sided p-value < 0.05 was considered as sta-
tistically significant. Analyses were done with R 3.2.1 
(codename ‘World-Famous Astronaut’; R Foundation 
for Statistical Computing; Vienna, Austria) addition-
ally using the packages plyr, sandwich, nlme, multcomp, 
pROC and ggplot2 [26].
Results
Cohort description
During the study period 135 patients were admitted at 
the hospital with malaria, and, 86 (63.7%) were included 
in the study (Fig.  1). Mean age was 21.5 (± 9.4) years, 
61 (71%) were male and 27 (32%) had KD [AKI = 15 
(55.6%) + AKD without AKI = 12 (44.4%)]. The KDIGO 
stage most prevalente was the stage 1 with 8 (29.7%) 
patients in this stage, other 4 (14.8%) patients were at 
the stage 2 and only 3 (11.1%) at stage 3. sCr and BUN of 
the KD group at admission (day 1) were 5.38 ± 5.42 and 
99.4 ± 61.9  mg/dL, respectively. Three patients (3.5%) 
received haemodialysis and eight (9.3%) patients died 
during the 4-days follow-up. Of those patients who died, 
5/8 (62.5%) had KD, compared to 3/8 (37.5%) with no 
KD (p = 0.047). Sixty percent of patients were undergo-
ing malaria treatment prior to the study recruitment and 
hospital admission (self-medication or first care in health 
care centres) (Table 1).
SUN and BUN measurements
While BUN was overestimated by SUN in this popula-
tion  (Table  2), there was a good directional agreement 
along the follow-up day’s period (day 1 to day 4) (Fig. 2). 
Plotting the differences (BUN–SUN midpoint) as a func-
tion of BUN a modified Bland–Altman plot showed a 
consistent non-significant bias with a proportional error 
(Fig. 3). The linear mixed effects model with SUN as the 
dependent variable and BUN as a fixed effect with ran-
dom intercept (individual patient) and random slope 
(individual observation day) showed a significant con-
tinuous association between SUN and BUN (0.40 mg/dL 
SUN per mg/dL BUN; p < 0.001).   
Diagnostic performance of SUN and BUN for AKI and AKD 
without AKI
For KD diagnosis of, the area under the receiver operator 
characteristics (ROC) curve for SUN ranged from 0.88 
(95% CI 0.79–0.96) on observation day 0 (screening day) 
to 0.87 (95% CI 0.71–1.0) on observation day 4 (Fig. 4), 
with the highest sensitivity (0.67) and specificity (0.98) at 
day 0, respectively. The optimal SUN threshold to diag-
nose KD in this population was test pad #5 (> 54 mg/dL), 
with a sensitivity of 67% and specificity of 98%.
Discussion
Statement of principal findings
Kidney disease is one of the most serious complications 
in patients suffering from Malaria and is an independent 
predictor of death [9]. The severe renal impairment dem-
onstrated in this study is an important finding and may 
represent the delay of the diagnosis and consequently 
delay to indicate the adequated treatment for malaria and 
Table 1 Descriptive analyses final cohort (N = 86)
KDIGO classification: (a) AKI stage 1: variation of 1.5–1.9 times baseline serum 
creatinine OR ≥ 0.3 mg/dL (≥ 26.5 mmol/L) increase; (b) AKI stage 2: variation 
of 2.0–2.9 times baseline serum creatinine; (c) AKI stage 3: variation of 3.0 
times baseline serum creatinine OR increase in serum creatinine to ≥ 4.0 mg/
dL (≥ 353.6 mmol/L) OR initiation of renal replacement therapy OR, in 
patients < 18 years, decrease in eGFR to < 35 mL/min per 1.73 m2
BUN blood urea nitrogen, sCR serum creatinine
Variable Value
Age (years) 21.5 ± 9.5
Male (N; %) 61 (71%)
Presence of kidney disease (N; %) 27 (32%)
BUN at day 1 (mg/dL) 39.5 ± 14.9
sCr at day 1 (mg/dL) 5.38 ± 5.42
KDIGO—AKI stage 1 (N; %) 8 (29.7%)
KDIGO—AKI stage 2 (N; %) 4 (14.8%)
KDIGO—AKI stage 3 (N; %) 3 (11.1%)
AKD no AKI (N; %) 12 (44.4%)
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AKI. The lack of laboratory resources or a bedside diag-
nostic tool in areas where the disease is highly prevalent 
can be one of the reasons for underdiagnosed kidney 
disease and increased mortality rate in this population. 
In the present study, one-third of patients admitted with 
malaria had some degree of KD. In these patients, the 
SUN dipstick showed reasonable sensitivity (67%) and 
an excellent specificity (98%) to detect KD, both at the 
moment of diagnosis and also in the follow-up.
Discussion in the light of other studies
Characteristics of the patient population
Patients hospitalized with malaria in the studied setting 
were younger than in most parts of the studies previously 
performed testing the SUN strip except for the study per-
formed in Malawi, in which similar mean age was found 
(301 patients, mean age 25.9 ± 6.45  years). In Brazilian 
cross sectional in which 44 patients were studied the 
mean age was 59.5 ± 18 years and in the follow up study 
Fig. 2 Scatter plot showing the relationship between salivary urea nitrogen and blood urea nitrogen on days 1–4. The red areas represent the 
ranges of the semiquantitative saliva urea nitrogen dipsticks
Fig. 3 Bland Altman plot showing the mean differences and 95% 
confidence intervals between BUN and SUN. SUN was transformed 
to a continuous variable by choosing the midpoint for each test pad 
range
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performed in Brazil and in the USA, 37 subjects evalu-
ated the mean age was 60 ± 19.1 years old [18, 19]. This 
finding also corroborates with the literature that shows 
KD, especially AKI, at the low resources setting is a dis-
ease which affects mainly young people and as a conse-
quence of community-acquired disease [12, 20, 27].
High incidence of AKD and comparisons to other studies
One-third (27%) of the population analysed in this study 
presented KD, in contrast to the findings of the previous 
studies performed in which, KD was defined as those 
patients with AKI and AKD no AKI. In the adult cohort 
in Malawi one-fifth (20%) of patients studied had KD and 
in the obstetric cohort one-sixth (13%) of patients were 
detected with the disease. These differences may be due 
to the delay those patients in seeking health care, or due 
to self-medication strategies that may be common where 
malaria is endemic. The frequency of malaria-associated 
AKI raised from 4.7% in 1983 to 1995 to 17.0% in 1996 to 
2008 in certain regions [28, 29] which may be related to 
Table 2 Median and  25th and  75th blood urea nitrogen 
percentiles corresponding to SUN test strip pads
Blood urea nitrogen
Pad SUN range (mg/dL) Count Median 25th percentile 75th percentile
1 5–14 65 7 6.07 8.4
2 15–24.9 75 11.8 10.27 14
3 25–34.9 34 17.03 15.5 21.35
4 35–54.9 18 30.1 24.5 39.02
5 55–74.9 31 40.13 32.76 74.82
6 > 75 52 113.87 76.89 162.05
The colour scheme in the left column indicates the test actual pad colours
SUN salivary urea nitrogen
Fig. 4 Diagnostic performance of SUN to detect kidney disease at days 1–4. The optimal diagnostic threshold as per Youden Index was SUN test 
pad #5 (SUN > 54 mg/dL)
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the reduction of AKI due to other causes (e.g. diarrhoea-
associated AKI), rather than changes in virulence of the 
protozoa.
Performance of SUN at the baseline and follow‑up
For the diagnosis of KD, the area under the receiver 
operator characteristics curve for SUN ranged from 0.88 
(95% CI 0.79–0.96) on observation Day 0 (screening day) 
to 0.87 (95% CI 0.71–1.0) on observation day 4 (Fig. 4), 
with the highest sensitivity (0.67) and specificity (0.98) at 
day 0, respectively. Similar findings were reported in our 
previous results with SUN demonstrating a adequated 
diagnostic performance with similar area under ROC 
(AUROC) especially at the admission, Malawi adults 
cohort with 0.82 (95% CI 0.77–0.85) and the Brazilian 
adult AKI cohort with an AUROC of 0.81 (CI 95% 0.63–
0.98) at day 0 [19, 20].
Reasons for the better results in comparison to the previous 
studies
The optimal threshold of SUN to detect kidney impair-
ment in the studied population was considerably higher 
(test-pad #5) as compared to other studies in AKI 
patients reported [18, 20]. A possible reason for that 
is explained by the higher sCr, BUN and SUN values at 
admission compared to other populations analysed in 
previous studies and the well described increased diag-
nostic performance of SUN strips at the higher levels of 
BUN. The severe renal impairment demonstrated in this 
group of patients is possibly due to the late admission, 
prolonged self-management without seeking medical 
attention, and long travel times [16, 30].
Study limitations
There are some limitations to the use of SUN dipsticks in 
general: (a) some bacteria in the oral cavity produce ure-
ase that may pre-analytically lower SUN levels and result 
in a spurious underestimation of BUN [31]; (b) patients 
with malaria are often dehydrated, resulting in BUN and 
SUN levels disproportionally increased compared to 
the kidney function; these circumstances may result in 
false positive KD diagnoses [10, 32]; (c) poor agreement 
between SUN and BUN at lower levels is evident in the 
current data and is consistent with  the previous work. 
While the exact reasons for this finding are still uncer-
tain, it indicates a need for further improvement of the 
test pads to increase the sensitivity to detect milder (i.e. 
earlier) stages of renal disease [18–20]. This study may 
further be limited in terms of generalizability which may 
be affected by the inclusion of patients at ages between 
11 and 50 years. Also the results regarding the mean age 
of the affected group could have change if older than 
50  years old subjects have been included in the study. 
While the risk of selection bias exists, the intention was 
to restrict the study to those that are most likely affected 
by malaria and whose kidney disease is essentially caused 
by malaria and not a reflection of a pre-existent chronic 
renal impairment, which could occurred if we included 
older people with previous chronic co-morbidities, such 
as hypertension and diabetes, or even in smaller children 
with acute episodes of renal impairment due to other 
infectious diseases.
Strength, interpretation and clinical implications
This is the first study that assessed the diagnostic per-
formance of SUN dipsticks to KD (AKI + AKD no AKI) 
detection in malaria patients. A satisfactory diagnostic 
accuracy was found which may favour the dipstick as to 
be considered a useful diagnostic tool to detect KD in 
this population. This could be enormously helpful and 
facilitate early diagnosis and treatment and increase the 
chances of renal recovery. In developing countries, the 
SUN dipstick could assist health care workers to diagnose 
AKI and AKD without AKI and facilitate triage and refer-
ral to secondary and tertiary hospitals. To what extent 
this will translate into an improved survival remains to 
be explored in future studies. Further developments may 
render the dipstick an important diagnostic tool for acute 
nephrology care in developing countries.
Conclusion
In this cohort, the SUN dipstick identified malaria 
patients with severe renal impairment with good diag-
nostic accuracy. SUN identified patients with severe renal 
impairment with sensitivity and specificity at acceptable 
levels for clinical care, rendering the dipstick useful in 
settings with limited resources. In line the previous work, 
this study corroborates SUN as a potentially helpful tool 
for the detection of acute renal disease in patients with 
malaria.
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